Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?

Daniel G. Hackam
CMAJ June 24, 2003 168 (13) 1689;
Daniel G. Hackam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.

Background: Cholesterol lowering with statins effectively reduces cardiovascular event rates in a broad array of individuals at high risk of vascular disease. There is limited information, however, on the benefits of statins in patients with well-controlled hypertension and average or low cholesterol levels.

Question: Does treatment with atorvastatin improve cardiovascular outcomes in patients with hypertension and additional vascular risk factors?

Design: The trial was a substudy of a large randomized controlled trial comparing 2 antihypertensive treatment strategies in 19 342 hypertensive outpatients 40 to 79 years of age with at least 3 additional cardiovascular risk factors. Patients included in the lipid-lowering arm had a total serum cholesterol level of 6.5 mmol/L or less. Exclusion criteria included previous myocardial infarction, currently treated angina, recent cerebrovascular event, fasting serum triglyceride level exceeding 4.5 mmol/L, symptomatic heart failure, uncontrolled arrhythmias or significant renal, hepatic or hematologic disease. The study design was double-blind, and end-point analyses were performed on an intention-to-treat basis. The trial was stopped early after an interim analysis showed clear evidence of efficacy.

Results: In all, 10 305 patients were randomly assigned to receive either atorvastatin (10 mg/d) or placebo and were followed up for a median of 3.3 years. Most participants were white (95%) and male (81%), with a mean age of 63 years. The mean serum total cholesterol level was 5.5 mmol/L in both groups; at the end of follow-up, it was 1.0 mmol/L lower in the atorvastatin group. The mean blood pressure was reduced from 164/95 mm Hg to 138/80 mm Hg in both groups by the end of the study.

The primary end point (incidence of nonfatal myocardial infarction and fatal coronary artery disease) was reduced by 36% in the atorvastatin group (95% confidence interval [CI] 17% to 50%; p < 0.001). The incidence of fatal and nonfatal strokes was reduced by 27% (95% CI 4% to 44%) and total coronary events by 29% (95% CI 14% to 41%), with a nonsignificant reduction in all-cause mortality of 13% (95% CI –6% to 29%). The incidence of chronic stable angina was reduced by 41% (95% CI 10% to 62%). The benefit of atorvastatin emerged in the first year of follow-up. The rate of serious adverse events did not differ significantly between the 2 groups.

Commentary: The positive findings of this trial are in keeping with those of a number of previous clinical trials showing the benefit of statins in patients at heightened vascular risk.1,2 However, the ASCOT-LLA extends this paradigm to patients with well-controlled hypertension and additional vascular risk factors. Several aspects of the ASCOT-LLA may have even underestimated the degree of benefit conferred by this therapy: crossover between the 2 groups was 21% after 3 years of follow-up, the study was stopped nearly 2 years earlier than most previous statin trials, blood pressure was being aggressively treated in both patient groups, and the dose of atorvastatin was not titrated from the starting dose of 10 mg/d. Higher doses would have resulted in substantially greater reductions in total cholesterol and low-density-lipoprotein (LDL) cholesterol levels, which in turn, given the current evidence, might well have led to even greater reductions in cardiovascular event rates.3

Practice implications: The mean total and LDL cholesterol levels in the ASCOT-LLA (5.5 and 3.4 mmol/L respectively), although comparable to those seen in Western countries, were substantially higher than those in many Asian populations. This may be one reason why the latter enjoy significantly lower rates of coronary artery disease and ischemic stroke.4 Even with intensive blood pressure control, high-risk patients with average or below-average cholesterol levels appear to derive significant additional benefit from statin therapy. The results of the ASCOT-LLA, therefore, reinforce the concept that initiating statin therapy should be informed more by consideration of the patient's global vascular risk than by the numeric value of an individual risk factor, such as systolic blood pressure or serum cholesterol level.

Daniel G. Hackam Chief Medical Resident St. Joseph's Healthcare Department of Medicine McMaster University Hamilton, Ont.

References

  1. 1.↵
    Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18(4):220-8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102 (2): 157-65.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104(23):2855-64.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 168 (13)
CMAJ
Vol. 168, Issue 13
24 Jun 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Daniel G. Hackam
CMAJ Jun 2003, 168 (13) 1689;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Daniel G. Hackam
CMAJ Jun 2003, 168 (13) 1689;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No absolutes
  • No absolutes
  • Google Scholar

More in this TOC Section

Practice

  • Chronic cutaneous ulcer from drug use
  • A low-barrier, flexible safe supply program to prevent deaths from overdose
  • Digital gangrene in a woman with scleroderma
Show more Practice

In the Literature

  • Does the choice of β-blocker affect outcome in chronic heart failure?
  • Bisphosphonates and skeletal morbidity in patients with metastatic cancer
  • ACE inhibition in stable coronary artery disease
Show more In the Literature

Similar Articles

Collections

  • Topics
    • Cardiology: hypertension
    • Cardiology: ischemic heart disease
    • Drugs: cardiovascular system
    • Stroke

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire